A new multi-year collaboration between a UK-based genomics data platform and an American genetics company is set to create the world's largest project of its kind to study Indian populations. Global Gene Corp believes its tie-up with US-headquartered Regeneron Genetics Center (RGC), a wholly-owned subsidiary of New York based Regeneron Pharmaceuticals Inc, is aimed at finding innovative diagnosis and therapies for rare diseases. “We believe that genomics will help India to achieve a paradigm shift in healthcare,” said Deepak Bagla, managing director and CEO of Invest India, the country's investment promotion and facilitation agency which is supporting Cambridge-headquartered Global Gene Corp to build world-class capabilities in Mumbai and Ahmedabad. Invest India said the latest collaboration marks a step forward in the Indian government's “Healthcare for All” plans, particularly with the Ayushmann Bharat initiative announced by Prime Minister Narendra Modi. “Genomic technology is important to achieve this mission. This investment by Global Gene Corp and Regeneron will create infrastructure, jobs and opportunity for the future in India,” Bagla noted.